

Name of the issue: Aster DM Healthcare Limited

Updated until September 30,2020

---

1	Type of issue (IPO/ FPO)	IPO
2	Issue size (Rs. in crore)	980.10
3	Grade of issue alongwith name of the rating agency	

Name	
Grade	Not Applicable

4	Subscription Level (Number of times) <sup>(1)</sup>	Overall 1.1731
---	---	----------------

Source: Post Issue Monitoring Report

(1) After technical rejections

5 QIB holding (as a %age of total outstanding capital) as disclosed to stock exchanges

Particulars	%
(i) On Allotment February 21, 2018 <sup>(1)</sup>	1.6736%
(ii) at the end of the 1st Quarter immediately after of the issue (March 31, 2018)	9.61%
(iii) at the end of 1st FY (March 31, 2018)	9.61%
(iv) at the end of 2nd FY (March 31, 2019)	9.74%
(v) at the end of 3rd FY (March 31, 2020)	17.32%

(1) Excluding Anchor investors and after technical rejections

6 Financials of the issuer

(Consolidated Rs. in crore)

Parameters	31-Mar-18	31-Mar-19	31-Mar-20
Net Sales/ Income from operations	6,721.16	7962.71	8738.50
Net Profit after Minority Interest	281.68	367.31	314.66
Equity Capital	505.22	505.23	499.52
Reserves excluding revaluation reserves	2,326.86	2708.73	2772.62

**7 Trading status in the scrip of the issuer**

Company's Equity Shares are listed on both the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE" )

Particulars	Status
(i) at the end of 1st FY (March 31, 2018)	Frequently traded on NSE and BSE
(ii) at the end of 2nd FY (March 31, 2019)	Infrequently traded on NSE and BSE
(iii) at the end of 3rd FY (March 31, 2020)	Frequently traded on NSE and infrequently traded on BSE

**8 Change, if any, in directors of issuer from the disclosures in the offer document**

Particulars	Name of Director	Appointed / Resigned
During year ended March 31, 2018	Not Applicable	
	Rajagopal Sukumar	Resignation
	Biju Varkkey	Appointment
During year ended March 31, 2019	Harsh Charandas Mariwala	Resigned
	Dr. Layla Mohamed	Appointment
During year ended March 31, 2020	Ms. Alisha Moopen**	Appointed
	Maniedath Madhavan	Resignation
	Suresh Muthukrishna Kumar	Re-appointed

\*\*Ms. Alisha Moopen was serving on the Board as a Non-Executive Director. She has been appointed as the Deputy Managing Director of the Company with effect from 7th August 2019

**9 Status of implementation of project/ commencement of commercial production**

Particulars	Remarks
(i) as disclosed in the offer document	
(ii) Actual implementation	Not Applicable
(iii) Reasons for delay in implementation, if any	

**10 Status of utilization of issue proceeds**

(i) as disclosed in the offer document

Expenditure Items	Amount	(Rs. Crore)	
		Estimated utilization up to March 31, 2018	Estimated utilization up to March 31, 2019
Pre-payment of debt	564.16	564.16	-
Purchase of medical equipment	110.31	30.00	
80.31			
General corporate purposes	1.52	2.13	11.51
Issue related expenses	49.01	32.81	4.08
<b>Total</b>	<b>725.00</b>	<b>629.10</b>	<b>95.90</b>

Source: Prospectus dated February 17, 2018

## (ii) Actual utilization

(Rs. Crore)

Expenditure Items	Amount to be financed from Gross Proceeds as disclosed in the offer document*	Amount utilized up to March 31, 2018 <sup>(1)</sup>	Amount utilized up to March 31, 2019 <sup>(2)</sup>	Amount utilized up to March 31, 2019 <sup>(3)</sup>	Amount utilized up to March 31, 2020 <sup>(4)</sup>
Pre-payment of debt	564.16	564.16	564.16	564.16	564.16
Purchase of medical equipment	110.31	-	38.44	92.15	108.8
General corporate purposes	6.21	2.13	6.21	6.21	6.21
Issue related expenses	44.32	32.81	44.32	44.32	44.32
<b>Total</b>	<b>725.00</b>	<b>599.10</b>	<b>653.13</b>	<b>706.84</b>	<b>723.49</b>

Source: Prospectus dated February 17, 2018, BSE Filing

(1) As disclosed to the stock exchange - Monitoring agency report dated May 19, 2018

(2) As disclosed to the stock exchange - Monitoring agency report dated May 28, 2019

(3) As disclosed in financials results reported to SEs

(4) As disclosed in FY20 Annual Report

(iii) Reasons for deviation, if any

Not Applicable

11 **Comments of monitoring agency, if applicable**

Particulars	Remarks
(i) Comments on use of funds	No comments
(ii) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	No deviation is observed in the utilisation of issue proceeds except to the payments made in relation to General Corporate Purposes has exceeded by Rs 4.69 crores owing to reduction in Issue Related Expenses by Rs. 4.69 crores adjusted under General Corporate Purpose head.
(iii) Any other reservations expressed by the monitoring agency about the end use of funds	None

Company has appointed Axis Bank Limited as the Monitoring Agency to monitor the utilization of the Net Proceeds

Source: As disclosed to the stock exchange - Monitoring agency report dated May 19, 2018

12 Price-related data

Designated SE BSE  
 Issue Price (Rs.) 190  
 Listing Date February 26, 2018

Price parameters	At close of listing day February 23, 2018	At close of 30th calendar day from listing day March 27, 2018	At close of 90th calendar day from listing day May 26, 2018 <sup>(1)</sup>	As at the end of March 31, 2018		
				Closing price during FY	High during FY	Low during FY
Market Price	179.85	164.35	179.80	167.20	187.80	140.10
Sensex	34,445.75	33,174.39	35,165.48	33,255.36	36,443.98	29,241.48
Sectoral Index	Not comparable to any of the available sectoral indices					
Price parameters	As at the end of March 31, 2019			As at the end of March 31, 2020		
	Closing price during FY	High during FY	Low during FY	Closing price during FY	High during FY	Low during FY
Market Price	154.55	191.75	142.20	95.5	180.5	78.5
Sensex	38,672.91	38,896.63	33,019.07	29,468.49	42,273.87	25,638.90
Sectoral Index	Not comparable to any of the available sectoral indices					

Source: Stock Exchange data. Where the 30th day / 90th day / March 31 of a particular year falls on a holiday, the immediately following trading day has been considered

13 Basis for Issue Price and Comparison with Peer Group & Industry Average

Accounting ratio	Name of company	Face Value (Rs.)	As disclosed in the offer document	At the end of 1st FY March 31, 2018	At the end of 2nd FY March 31, 2019	At the end of 3rd FY March 31, 2020
	<b>Issuer: Consolidated</b>	10	4.29	5.75	6.63	5.51
	<b>Peer Group:</b>					
EPS P/E	Apollo Hospitals Enterprise Limited	5	15.9	8.4	17.0	32.7
	Fortis Healthcare Limited	10	9.2	-19.5	-3.7	0.8
	Narayana Hrudayalaya Limited	10	4.1	2.5	2.9	5.9
	Healthcare Global Enterprises Limited	10	2.7	2.4	-2.8	-12.1
	Industry Avg					
	<b>Issuer: Consolidated</b>	10.0	44.3	29.1	23.3	17.3
	<b>Peer Group:</b>					
RoNW%	Apollo Hospitals Enterprise Limited	5.0	75.9	125.9	69.8	34.8
	Fortis Healthcare Limited	10.0	17.4	NA	NA	163.7
	Narayana Hrudayalaya Limited	10.0	72.8	110.1	73.6	42.2
	Healthcare Global Enterprises Limited	10.0	103.8	123.1	NA	
	NA Industry Avg					
	<b>Issuer: Consolidated</b>	10	10.6%	9.9%	11.4%	9.6%
	<b>Peer Group:</b>					
NAV per share based on balance sheet	Apollo Hospitals Enterprise Limited	5	2.3%	1.8%	6.0%	
	13.0% Fortis Healthcare Limited	10	7.6%	NA	NA	
	1.4% Narayana Hrudayalaya Limited	10	8.6%	4.9%	5.5%	
	10.5% Healthcare Global Enterprises Limited	10	5.3%	3.5%	NA	
	-32.9% Industry Avg:			-	-	
	<b>- Issuer: Consolidated</b>	10.0	40.5	56.1	63.6	
	65.5					
	<b>Peer Group:</b>					
	Apollo Hospitals Enterprise Limited	5.0	281.7	232.3	239.8	239.5
	Fortis Healthcare Limited	10.0	121.9	78.3	87.4	88.2
	Narayana Hrudayalaya Limited	10.0	47.1	0.5	52.9	55.6
	Healthcare Global Enterprises Limited	10.0	50.5	0.6	62.1	43.0
	Industry Avg:					

(1) P/E ratio is calculated as closing share price on BSE / Basic EPS for year ended

(2) EPS is as reported in the audit report filed with the stock exchanges

(3) Net Worth includes Equity Share Capital and Reserves & Surplus (excluding revaluation reserves)

(4) RoNW is calculated as Net Income (as defined above) / Closing Net Worth (as defined above)

(5) NAV per share is calculated as Net Worth / Equity Shares Outstanding

#### 14 Any other material information

Particulars	Date
Ms. Puja Aggarwal has been appointed as Company Secretary and Compliance officer pursuant to the provisions of Section 203 of the Companies Act, 2013 and Regulation 6 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015	August 14, 2018
Mr. Thomas Joseph has resigned from the position of the Compliance Officer of the Company with effect from the closure of business hours on 14th August, 2018.	August 14, 2018
Mr. Thomas Joseph was appointed as the compliance officer under Regulation 6 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 from May 21, 2018.	June 2, 2018
The Board of Directors at its meeting held on 21st May 2018 had accepted the resignation of Mr. Rajesh A, Company Secretary and Compliance Officer of the Company. Board had resolved to relieve Mr. Rajesh A from his duties from the close of business hours on May 31, 2018	May 23, 2018
Aster DM Healthcare, a leading healthcare service provider in India and in GCC with presence in 9 countries, has entered into an agreement with Subramanya Constructions & Development Company Limited (SCDC), a leading real estate developer, to construct a new hospital in Chennai. This 500 bedded, state of the art, multi-specialty hospital is expected to be commissioned in 2020. The hospital, which would be situated at a prime location in Chennai, will provide advanced healthcare services to the residents of Tamil Nadu and customers from other states in India as well as overseas. Aster DM Healthcare, which was recently listed at NSE and BSE already operates 11 hospitals in South India with 4037 installed beds. The new facility is in line with Aster DM's strategy of strengthening its presence in India.	April 12, 2018
Aster DM Healthcare ("Aster DM") had opened a 150 bed multispeciality hospital in Al Qusasis, Dubai, UAE.	Jan 29, 2019
The Company subscribed to the unsubscribed portion of the rights issue in Malabar Institute of Medical Sciences Limited ("MIMS"), a subsidiary, on 27th December 2019 which led to a further increase in the holding by 0.70%, thereby making the shareholding of the Company 73.22% in MIMS. The aggregate increase in the shareholding of the Company is 2.54%	March 1, 2019
Company converted CCPS to equity shares on 28th February 2019 in Prerana Hospital Limited, subsidiary thereby increasing the shareholding of the Company to 84.93%	March 1, 2019
Ms. Alisha Moopen has been appointed as the Deputy Managing Director of the Company for a term of 5 years with effect from August 7, 2019, subject to the approval of the Central Government and the Shareholders.	August 7, 2019
Dr. Layla Mohamed Hassan Ali AL Marzooqi (DIN: 0008401425), Independent Director of the Company, has been appointed as a Director on the Board of	September 4, 2019
Aster OM Healthcare FZC, an unlisted material subsidiary of the Company, with effect from 3rd September 2019	September 12, 2019
Shifting the registered office of the Company from the State of Kerala to the State of Karnataka	
Sri Sainatha Multispeciality Hospitals Private Limited is a subsidiary of Aster DM Healthcare Limited ("Company") which was incorporated on 24 May 2007 and it operates a hospital in Hyderabad, Telangana. The Company held 58.03% Class B Equity Shares and the promoter, along with other investors held 41.97% Class B equity shares of Sri Sainatha Multispeciality Hospitals Private Limited. Based on the terms of the Shareholders Agreement, the promoters and investors decided to exercise the put option. Pursuant to the exercise of put option by the promoters of Sri Sainatha, the shareholding of the Company increased by 9.49%, thereby making the aggregate shareholding of the Company 67.52% in the Class B equity shares of Sri Sainatha Multispeciality Hospitals Private Limited.	September 12, 2019
Mr. Suresh Muthukrishna Kumar (DIN: 00494479), Independent Director of the Company, has been appointed as a Director on the Board of Med care Hospital LLC, an unlisted material subsidiary of the Company pursuant to increase in the shareholding in step-down subsidiary, Medcare Hospital LLC, UAE.	September 30, 2019
Medcare Hospital LLC is a step-down subsidiary of Aster DM Healthcare Limited ('Company') which was incorporated on August 16, 2006 and it operates hospitals in UAE. The Company, through its Subsidiary, Aster DM Healthcare FZC, holds aggregate economic interest of 80% in Medcare Hospital LLC. Pursuant to the Share Sale Agreement notarization completed on 29 September 2019, the Company has acquired additional 5% stake in Medcare Hospital LLC, increasing the aggregate beneficial shareholding of the Company to 85% in Medcare Hospital LLC.	September 30, 2019

pursuant to the exercise of put option by the promoters of Sri Sainatha Multispeciality Hospital Private Limited , the shareholding of the Company in class B equity shares of Sri Sainatha Multispeciality Hospital Private Limited has increased by 4.89%, thereby making the aggregate shareholding of the Company 72.41%. In this regard, as per Circular Number CIR/CFD/CMD/4/2015 dated September 09, 2015 pertaining to continuous disclosure requirements for Listed Entities under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements)	October 1, 2019
The Company, through its Subsidiary, Aster DM Healthcare FZC, has entered into a Share Purchase Agreement on October 30, 2019, to acquire 80% stake in Premium Healthcare Limited, UAE. The target entity is in the business of running and operating a Clinic at Dubai International Financial Centre. The acquisition of shares is likely to be completed by December 31, 2019.	October 31, 2019
With reference to the captioned subject, we would like to inform that Aster DM Healthcare FZC (step-down subsidiary of Aster DM Healthcare Limited), has incorporated a Limited Liability Company, Aster Alfaone FZ LLC, in Dubai..	October 31, 2019
Mr. Ravi Prasad (DIN: 07022310), Independent Director of the Company, has been appointed as a Director on the Board of Affinity Holdings Private Limited, an unlisted material subsidiary of the Company in Mauritius , with effect from September 23,2019.	November 5, 2019
pursuant to the exercise of put option by the promoters of Sri Sainatha Multispeciality Hospital Private Limited , the shareholding of the Company in class B equity shares of Sri Sainatha Multispecialty Hospital Private Limited has increased by 4.89%, thereby making the aggregate shareholding of the Company 77.30%.	November 23, 2019
In furtherance to the announcement made by the Company on October 31, 2019 on the Captioned subject the Company through its Subsidiary, Aster DM Healthcare FZC, Completed acquisition of 80% stake in Premium Healthcare Limited, UAE on December 5, 2019 and confirmation received by the Company from Dubai International Financial Centre Authority (DIFCA) on December 08, 2019.	December 9, 2019
The Company held 84.93% equity shares of Prerana Hospital Limited. Pursuant to the exercise of put option by the promoters of Prerana Hospital Limited, the shareholding of the Company in Prerana Hospital Limited has increased by 2.06%, thereby making the aggregate shareholding of the Company to 86.99%.	December 12, 2019
the Company had decided to close the operations of its loss-making clinics in Philippines by December 31, 2019.	December 13, 2019
Company through its Subsidiary, Aster DM Healthcare FZC, has entered into a Share Purchase Agreement to acquire 100% stake in Wahat Al Aman Home Healthcare LLC, Abu Dhabi on December 30, 2019 which will be EPS accretive.	December 31, 2019
approved a proposal to Buy-back up to 57,14,285 (Fifty seven lakhs fourteen thousand two hundred and eighty five only) equity shares of the Company for an aggregate amount not exceeding Rs. 120 crores (Rupees One Hundred and Twenty Crores only) (the 'Buyback Size'), being 1.13% of the total paid-up equity share capital, at Rs. 210 (Rupees Two Hundred and Ten only) per equity share (the 'Buyback').	January 09, 2020
the Company received approval of the UAE Government to hold 100% legal ownership in the subsidiaries in Emirate of Dubai, which contributes majority of the GCC business.	February 12, 2020
Central Government has granted approval for the re- appointment of Dr. Azad Moopen as Managing Director of the Company with effect from December 01, 2019 for a period of 3 years, 4 months and 13 days i.e upto April 14, 2023 on which date Dr. Azad Moopen shall be attaining the age of 70 years	March 11, 2020
Completion of 57,14,285 fully paid-up Equity Shares of face value of Rs. 10/- each of the Company at a price of Rs. 210/-	March 17, 2020
Aster DM Healthcare Limited ('the Company') has been operating pharmacies in Kuwait though its subsidiary, Aster Kuwait Pharmaceuticals and Medical Equipment Company W.L.L ('the Subsidiary') which contributes towards 0.42% of the consolidated revenue of the Company. please be informed that the Company intends to exit from the Kuwait market by shutting down the loss making operations of the pharmacies.	March 30, 2020
EMED Human Resources India Private Limited ('EMED') is an associate company of Aster DM Healthcare Limited ('the Company') in which the Company has 33.33% stake. The Company, through its wholly owned subsidiary, DM Med City Hospitals (India) Private Limited, has acquired 100% stake in EMED. Pursuant to the aforementioned acquisition the shareholding of the Company has increased from 33.33% to 100%, thereby making EMED a wholly owned step-down subsidiary of the Company.	March 31, 2020

Pursuant to regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018, Confirmation Certificate for the quarter ended March 31, 2020, is submitted.	
The Company has ensured and complied with all the activities pertaining to share transfers, both in physical and electronic mode. In this regard, the Company has appointed Link Intime India Private Limited, which is a SEBI approved category-I Registrar & Transfer Agent (RTA), registered with Securities and Exchange Board of India (SEBI Registration Number: INR000004058) for providing registry and share transfer services.	11- Apr-20
Pursuant to regulation 40 (9) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, the certificate issued by a Practicing Company Secretary, pertaining to transfer of shares and issue of share certificates for the half year ended March 31, 2020, is submitted.	
Statement of Investor Complaints for the quarter ended March 2020	
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, upon recommendation of Nomination and Remuneration Committee, the Board of Directors of the Company, vide circular resolution passed on April 11, 2020, have appointed Mr. Chenayappillil John George (DIN: 00003132), as an Additional (Non-executive Independent) Director with effect from April 11, 2020, for a period of three years, subject to approval of the shareholders at the ensuing Annual General Meeting.	13-Apr-20
The following Non-executive Independent Directors of the Company have retired, effective April 20,2020 (close of business hours) upon completion of their term:	
Mr. Ravi Prasad	20-Apr-20
Mr. Daniel James Snyder	
Press Release titled 'Aster Clinical Lab LLP (Aster Labs) started testing COVID-19 RT-PCR confirmatory test at Bengaluru'.	6-May-20
Dr. Layla Mohamed Hassan Ali Almarzooqi (DIN: 0008401425), an Independent Director of the Company, has been appointed as a Director on the Board of Affinity Holdings Private Limited, an unlisted material subsidiary of the Company in Mauritius, vide the resolution passed on May 12, 2020.	13-May-20
Press release titled 'Social Alpha and Aster DM Healthcare collaborate to launch Aster - Social Alpha Co-Innovation and Clinical Practice Integration Initiative for Digital Health and MedTech Start-ups'.	19-May-20
The Company through its Wholly owned Subsidiary Companies, has acquired 100% stake in Warseps Healthcare LLP and acquisition is expected to complete on May 25, 2020.	23-May-20
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/84 dated May 20, 2020, the impact of COVID-19 on the business and operations of the Company, is submitted.	1-Jun-20
Press release titled 'Aster DM Healthcare launches 50 bed critical care Aster Hospital in Muhaisnah, Dubai'.	
The Company informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/06/2020 ,inter alia, to consider and approve the Audited Financial Results (both standalone and consolidated) of the Company for the quarter and year ended March 31, 2020	8-Jun-20
The Exchange has sought clarification on June 17, 2020, with reference to Movement in Volume.	17-Jun-20
With reference to Movement in Volume, the Company has submitted to BSE a copy of Clarification.	18-Jun-20
<ol style="list-style-type: none"> <li>1. The Meeting of the Board of Directors commenced at 11.30 am (IST) and concluded at 3.45 pm (IST).</li> <li>2. The audited financial results (standalone and consolidated) of the Company for the quarter and year ended March 31, 2020 together with the Auditor's Report has been reviewed by the Audit Committee and considered and approved by the Board of Directors</li> <li>3. The Board of Directors, on recommendation of Nomination and Remuneration Committee, have appointed Mr. James Mathew (DIN:07572909) as an Additional Director (Non-executive Independent).</li> <li>4. The 12th Annual General Meeting ("AGM") of the Company shall be held on August 14, 2020. The cut-off date for determining the eligibility of shareholders to vote on the resolutions proposed at the 12th Annual General Meeting of the Company has been fixed as August 07, 2020.</li> </ol>	
Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2020 duly reviewed by the Audit Committee and considered and approved by the Board of Directors.	23-Jun-20
The Company has informed BSE about Outcome of Board Meeting held on June 23, 2020.	
The Investor Presentation on the Company's performance for the quarter and year ended March 31, 2020, is submitted.	
Pursuant to the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company, at its meeting held, June 23, 2020, have considered and approved the appointment of Mr. James Mathew (DIN: 07572909) as an Additional Director (Non-executive Independent Director) of the Company with effect from June 23, 2020, for a period of three years subject to approval of the shareholders at the ensuing Annual General Meeting	
The report issued by Axis Bank Limited, Monitoring Agency appointed to monitor the utilization of proceeds of the Initial Public Offer, for the quarter ended	



---

March 31, 2020.

---

Pursuant to regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular no: CIR/CFD/CMD1/27/2019 dated February 8, 2019, the Annual Secretarial Compliance Report of the Company for the financial Year ended March 31, 2020, is submitted.

---

The revised Investor Presentation on the Company's performance for the quarter and year ended March 31, 2020, is submitted.

---

Due to technical distortion while converting the document to machine readable format the slides in the presentation are not appearing clearly.

---

The revised slide on the maturity profile of the hospitals in India (slide number 29 of the presentation uploaded on June 23 2020) which is a part of the Investor Presentation on the Company's performance for the quarter and year ended March 31, 2020.

24-Jun-20

---

Pursuant to Regulation 30 of SEBI Listing Regulations, the copies of newspaper advertisement published in Financial Express (English Language) and Mangalam (Malayalam Language, in compliance with Ministry of Corporate Affairs Circular No. 20/2020 dated May 5, 2020, intimating that 12th Annual General Meeting of the Company will be held on Friday, August 14, 2020 at 11.00 AM (IST) through Video Conferencing / Other Audio Visual Means, are submitted.

11-Jul-20

---

Pursuant to Regulation 30 of SEBI Listing Regulations, the copies of newspaper advertisement published in Financial Express (English Language) and Mangalam (Malayalam Language, in compliance with Ministry of Corporate Affairs Circular No. 20/2020 dated May 5, 2020, intimating that 12th Annual General Meeting of the Company will be held on Friday, August 14, 2020 at 11.00 AM (IST) through Video Conferencing / Other Audio Visual Means, are submitted.

11-Jul-20

---

Pursuant to regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, Confirmation Certificate for the quarter ended June 30, 2020, is submitted.

14-Jul-20

---

Statement of Investor Complaints for the quarter ended June 2020

---

Mr. Sharfuldeen Valiyapeedika Kandy undertook trades of sale of 40,000 shares as on Feb 12,2020 and 40,000 shares on August 26,2020 without seeking necessary pre-clearance from the Compliance

21-Sep-20

---

*Source- Stock Exchange filings*

For further updates and information, please refer stock exchange websites i.e. [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com)